Press Releases

PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP ANNOUNCES THE APPOINTMENT OF NEW BOARD MEMBERS AND GRANT OF STOCK OPTIONS. QUEBEC, – May 12, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB : DVHGF), a clinical late stage...

PRESS RELEASE For immediate release Devonian Announces Filing of Preliminary Base Shelf Prospectus QUEBEC, May 11, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation,...

PRESS RELEASE For immediate release Devonian Announces Approval of Amendments to its Stock Option Plan and its Restricted Share Unit Plan Not for distribution to United States newswire services or for dissemination in the United States QUEBEC, March 30th, 2023 –...

PRESS RELEASE For immediate release Devonian Health Group Announces Hybrid Shareholders’ Annual General and Special Meeting QUEBEC, February 22nd, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical...

PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP ANNOUNCES ITS PARTICIPATION AT BIO CEO & INVESTOR CONFERENCE QUEBEC, January 26, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical...

PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP ANNOUNCES EXECUTIVE CHANGE AND GRANT OF STOCK OPTIONS   QUEBEC, January 6, 2023 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical stage botanical...

PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP INC. TO PARTICIPATE IN THREE RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES.   QUEBEC, October 24, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD; OTCQB: DVHGF), a clinical...

PRESS RELEASE For immediate release DEVONIAN TO PRESENT THYKAMINE™ PHASE 2 CLINICAL RESULTS AT THE 6th DERMATOLOGY DRUG DEVELOPMENT SUMMIT FOR IINFLAMMATORY SKIN DISEASES.   QUEBEC, October 12, 2022 – Devonian Health Group Inc. (“Devonian” or the “Corporation”)...

PRESS RELEASE For immediate release Devonian Health Group Announces Peer-reviewed publication of Thykamine™ positive phase 2 clinical trial results in Journal of Drugs in Dermatology.   Clinical Study demonstrated dual benefit mode of action of Thykamine™ in...